Tau is a major therapeutic target for PSP and other tau-depositing neurodegenerative diseases, which are currently focused on the elimination of pathological aggregates from the brain or directly targeting MAPT gene expression with antisense oligonucleotide (ASO) therapies to inhibit tau aggregation [5, 34, 52, 57, 63]. Here, MAPT is linked to supranuclear palsy, progressive, 1.